---
title: "Bezuclastinib in Gastrointestinal stromal tumor: Product information and disease description"
description: "Formulary evidence on Bezuclastinib in Gastrointestinal stromal tumor: Product information and disease description. Covers Product description and Place of product in therapy. 63 evidence topics quoted from 47 sources."
canonical: "https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Bezuclastinib in Gastrointestinal stromal tumor: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Orphan designation and regulatory status

> “Date Designated: 07/21/2021”
> “Not FDA Approved for Orphan Indication”

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=827121)

<a id="topic-2.1.1-2"></a>

##### Special FDA designations

> “has granted Breakthrough Therapy Designation (BTD) for bezuclastinib in combination with sunitinib”

Source: [Cogent Biosciences GIST Breakthrough Therapy designation announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-breakthrough-therapy-designation)

<a id="topic-2.1.1-3"></a>

##### Regulatory status: Under review; NDA submitted April 2026 and accepted May 2026

> “November 5, 2026”
> “Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026”

Source: [Cogent Biosciences third quarter 2026 financial results (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-12)

> “May 28, 2026”
> “today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib. The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026.”

Source: [Cogent Biosciences GIST new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-0)

> “April 1, 2026”
> “Bezuclastinib NDA submitted under the FDA’s RTOR program”
> “today announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST)”

Source: [Cogent Biosciences GIST new drug application submission announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-submission-new-drug-application-0)

<a id="topic-2.1.1-4"></a>

##### Priority review and advisory committee

> “has granted the application Priority Review”
> “there is no plan to hold an advisory committee”

Source: [Cogent Biosciences GIST new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-0)

<a id="topic-2.1.1-5"></a>

##### Anticipated FDA approval date

> “Potential FDA approval of bezuclastinib in GIST”
> “PDUFA date of November 30, 2026”

Source: [Cogent Biosciences second quarter 2026 results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-11)

<a id="topic-2.1.1-6"></a>

##### Launch: Anticipated in the second half of 2026

> “Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026”

Source: [Cogent Biosciences third quarter 2026 financial results (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-12)

> “pending regulatory approval, the company expects to launch bezuclastinib commercially in the United States in the second half of 2026.”

Source: [Cogent Biosciences investor overview](https://investors.cogentbio.com/)

> “Pending FDA approval(s), launch bezuclastinib in the second half of 2026”

Source: [Cogent Biosciences first quarter 2026 financial results (2026)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm)

> “the NDA for GIST is also under FDA review, with a PDUFA target action date of November 30, 2026”
> “ready for the potential launches later this year”

Source: [Cogent Biosciences AdvSM new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-1)

<a id="topic-2.1.1-7"></a>

##### PEAK extension: first-line KIT exon 9-mutant GIST

> “a single-arm, 40 patient extension cohort of the PEAK trial”
> “first-line GIST patients with KIT exon 9 primary mutations”

Source: [Cogent Biosciences second quarter 2026 results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-11)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Cogent Biosciences

> “Sponsor: Cogent Biosciences, Inc.”

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=827121)

<a id="topic-2.1.2.1-2"></a>

###### Product names and molecular targets

> “Bezuclastinib (CGT9486, formerly PLX9486) is an investigational TKI that inhibits mutations in KIT exons 9, 11, 17, and 18.”

Source: [Cogent Biosciences ASCO poster (2023)](https://www.cogentbio.com/wp-content/uploads/2023/06/CogentBio_ASCO-2023-Peak.pdf)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational tablet formulation

> “600 mg dose of our new formulation of bezuclastinib, supplied as 75 mg tablets”

Source: [Cogent Biosciences Form 10-K (2023)](https://www.sec.gov/Archives/edgar/data/1622229/000095017023007729/cogt-20221231.htm)

Additional sources: [ChemScene (2025)](https://www.chemscene.com/quality-control.html?q=MSDS%2FMSDS%23USA%23CS%23CS-0376032.pdf)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Pharmacologic classification

> “protein tyrosine kinase inhibitor”

Source: [National Cancer Institute Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bezuclastinib)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Orphan-designated indication

> “Orphan Designation: Treatment of gastrointestinal stromal tumors (GIST)”

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=827121)

<a id="topic-2.1.2.5-2"></a>

###### Anticipated indication after prior imatinib

> “patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib.”

Source: [Cogent Biosciences GIST new drug application submission announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-submission-new-drug-application-0)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Drug class and mechanism

> “An orally bioavailable protein tyrosine kinase inhibitor of mutated forms of the tumor-associated antigen mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity.”

Source: [National Cancer Institute Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bezuclastinib)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical xenograft evidence

> “PLX9486 showed anti-tumor efficacy in patient-derived imatinib-resistant GIST xenograft models, mainly through inhibition of KIT signaling.”

Source: [Gebreyohannes et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30523507/)

<a id="topic-2.1.2.6.2-2"></a>

###### KIT resistance mechanisms and preclinical inhibitor testing

> “drugs in clinical development that potently inhibit most KIT AP or AL mutations exhibit poor activity against AP/AL mutations”

Source: [Mühlenberg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095889/)

Additional sources: [Guarnieri et al. (2022)](https://aacrjournals.org/cancerres/article/82/12_Supplement/147/700903/Abstract-147-Bezuclastinib-is-a-differentiated-KIT)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics: PLX9486 phase 1b/2a study

> “a mean terminal half-life of 71 hours”

Source: [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### PEAK eligibility: adult participants

> “Open to people ages 18 years and up”

Source: [University of California San Diego](https://clinicaltrials.ucsd.edu/trial/NCT05208047)

<a id="topic-2.1.2.8-2"></a>

###### Organ impairment and pregnancy

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Bezuclastinib

<a id="topic-2.1.2.9.1-1"></a>

###### Sunitinib combination pharmacokinetics

> “Combination with sunitinib did not have an impact on PK of bezuclastinib”

Source: [Cogent Biosciences CTOS poster (2023)](https://www.cogentbio.com/wp-content/uploads/2023/11/CogentBio_CTOS-2023-Peak-TiP_final.pdf)

<a id="topic-2.1.2.9.1-2"></a>

###### PEAK exclusion criterion: CYP3A4 modifiers

> “Received strong CYP3A4 inhibitors or inducers”

Source: [University of California San Diego](https://clinicaltrials.ucsd.edu/trial/NCT05208047)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Bezuclastinib on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Drug interaction: PEAK Part 1

> “Combination with bezuclastinib”
> “26% and 35% reduction in median and geometric mean steady state AUC (AUCss), respectively, of combined sunitinib + its active metabolite”

Source: [Cogent Biosciences CTOS poster (2023)](https://www.cogentbio.com/wp-content/uploads/2023/11/CogentBio_CTOS-2023-Peak-TiP_final.pdf)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### PEAK investigational combination regimen

> “bezuclastinib 600 mg QD + sunitinib 37.5 mg QD”

Source: [Wagner et al. (2024a)](https://www.cogentbio.com/wp-content/uploads/ASCO-2024-Peak-Part-1.pdf)

Additional sources: [Wagner et al. (2024b)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.11533)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Oral administration

> “Upon oral administration, bezuclastinib binds to and inhibits specific c-Kit mutants.”

Source: [National Cancer Institute Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bezuclastinib)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Expanded access

> “The patient must reside in the United States.”
> “Requests for expanded access must be submitted voluntarily by the patient’s treating physician.”

Source: [Cogent Biosciences](https://cogentbio.com/bezuclastinib/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Sunitinib in the investigational combination

> “sunitinib 37.5 mg QD”

Source: [Wagner et al. (2024a)](https://www.cogentbio.com/wp-content/uploads/ASCO-2024-Peak-Part-1.pdf)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Bezuclastinib on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### PEAK comparison with sunitinib monotherapy

> “mPFS, as assessed by blinded independent central review, was 16.5 months for the bezuclastinib combination vs. 9.2 months for sunitinib monotherapy.”

Source: [Cogent Biosciences GIST new drug application submission initiation announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-initiate-new-drug-application-nda-submission)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Mesenchymal tumors of the digestive tract

> “Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract”

Source: [Hirota et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9438854/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Gastrointestinal stromal tumor

<a id="topic-2.2.1.2.1-1"></a>

###### U.S. epidemiology

> “Annual age-adjusted incidence rose from 0.55/100,000 in 2001 to 0.78/100,000 in 2011 and increased with age, peaking among 70-79 year olds (3.06/100,000).”

Source: [Ma et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4294949/)

Additional sources: [Søreide et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26618334/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Gastrointestinal stromal tumor

<a id="topic-2.2.1.2.2-1"></a>

###### Preimatinib prevalence in a western Sweden population-based cohort

> “The prevalence of all GIST risk groups was 129 per million”

Source: [Nilsson et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15648083/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### U.S. survival in the population-based incidence study

> “The study period had 5-year overall and GIST-specific survival rates of 65% and 79%, respectively.”

Source: [Ma et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4294949/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Constitutive KIT activation

> “All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).”

Source: [Hirota et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9438854/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Mutational analysis before medical treatment

> “It is strongly recommended to perform the mutational analysis in all GIST cases requiring medical treatment (II, A).”

Source: [Serrano et al. (2023)](https://link.springer.com/article/10.1007/s12094-023-03177-7)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Bleeding and anemia

> “GI bleeding (most common presentation), which may be acute (melena or hematemesis) or chronic, resulting in anemia.”

Source: [National Cancer Institute GIST Treatment PDQ](https://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq)

<a id="topic-2.2.1.6-2"></a>

###### Obstruction, swallowing difficulty, and early satiety

> “GI obstruction.”
> “Dysphagia.”
> “Early satiety.”

Source: [National Cancer Institute GIST Treatment PDQ](https://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq)

<a id="topic-2.2.1.6-3"></a>

###### Pain

> “Pain.”

Source: [National Cancer Institute GIST Treatment PDQ](https://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Rectal GIST close to the anal sphincter: surgical morbidity

> “abdominoperineal resection with permanent colostomy is required.”

Source: [Serrano et al. (2023)](https://link.springer.com/article/10.1007/s12094-023-03177-7)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Gastrointestinal stromal tumor

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Humanistic burden

> “Severe fatigue occurs in 30% of GIST patients and in 33% of GIST patients on a TKI.”

Source: [Poort et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27233141/)

<a id="topic-2.2.1.8.1-2"></a>

###### Quality of life, fear of recurrence, and adherence during imatinib treatment

> “Approximately 3 out of 4 patients report high fear of cancer recurrence / progression”
> “Therapy adherence was high (96.1%).”

Source: [Westerdijk et al. (2026)](https://link.springer.com/article/10.1007/s12029-026-01417-x)

<a id="topic-2.2.1.8.1-3"></a>

###### Patient-reported symptoms

> “Fatigue and muscle pain or cramps were reported most frequently.”

Source: [den Hollander et al. (2022)](https://link.springer.com/article/10.1007/s00520-022-06929-3)

<a id="topic-2.2.1.8.1-4"></a>

###### Systematic review of quality of life and adverse events

> “A total of 104 papers were included; 13 studies addressed HRQoL, and 96 studies investigated adverse events.”

Source: [van de Wal et al. (2022)](https://pure.eur.nl/en/publications/health-related-quality-of-life-and-side-effects-in-gastrointestin/)

<a id="topic-2.2.1.8.1-5"></a>

###### Health-state utilities from GRID

> “Mean baseline utility was 0.767 (SD 0.221)”
> “The first post-progression health state was 0.647 (SD 0.343)”

Source: [Poole et al. (2015)](https://link.springer.com/article/10.1007/s10120-014-0391-x)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### GIST recurrence costs

> “The total healthcare cost was significantly higher for patients with GIST recurrence, with a difference of $4464 per patient per month (p < 0.01).”

Source: [Guérin et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25422992/)

<a id="topic-2.2.1.8.2-2"></a>

###### Hospital utilization

> “The study analyzed 48,690 hospitalizations”
> “with a primary diagnosis of GIST between 2016 and 2020.”

Source: [Sonaiya et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11882225/)

<a id="topic-2.2.1.8.2-3"></a>

###### Mutation testing and subsequent treatment

> “Dropout to/for further lines of treatment was 15% for patients with a Tested mutation vs. 47% in Untested patients.”

Source: [Call et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37143339/)

<a id="topic-2.2.1.8.2-4"></a>

###### U.S. inpatient burden

> “In 2009, there were 14,562 hospitalizations among patients with GISTs at a rate of 44/100,000 admissions.”

Source: [Datar and Khanna (2012)](https://jgo.amegroups.org/article/view/605/html)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Gastrointestinal stromal tumor on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Individual family account: medication costs and copay assistance

> “hundreds of dollars just for a single pill”
> “This funding is enough to cover my mother’s drug copay liability for 2022”

Source: [Accessia Health (2022)](https://accessiahealth.org/living-with-gist/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Tumor gene testing and tailored first-line therapy

> “an increase of 0.10 QALYs at a cost of $9513 compared with the empirical imatinib approach”
> “an incremental cost-effectiveness ratio of $92 100.”

Source: [Banerjee et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7522695/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Active Surveillance

<a id="topic-2.2.2.1.1-1"></a>

###### Small tumors with a mitotic index of 5 or less per 50 high-power fields

> “Endoscopic surveillance is an option for patients with tumors measuring 2 cm or smaller”

Source: [National Cancer Institute GIST Treatment PDQ](https://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Surgical Resection

<a id="topic-2.2.2.1.2-1"></a>

###### Surgery for localized disease

> “Approximately 70% of patients with GIST will be cured by surgery alone”

Source: [Serrano et al. (2023)](https://link.springer.com/article/10.1007/s12094-023-03177-7)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 KIT and PDGFRA Tyrosine Kinase Inhibitors

<a id="topic-2.2.2.1.3-1"></a>

###### First-line treatment of advanced or metastatic GIST

> “Imatinib”
> “a category 1 preferred first-line treatment option for patients with advanced or metastatic GIST with imatinib-sensitive mutations”

Source: [NCCN (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10245542/)

<a id="topic-2.2.2.1.3-2"></a>

###### PDGFRA D842V-mutant GIST: first-line therapy

> “avapritinib is used as first-line therapy”

Source: [National Cancer Institute GIST Treatment PDQ](https://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq)

<a id="topic-2.2.2.1.3-3"></a>

###### Second-line treatment after imatinib failure

> “After the failure of imatinib, the standard second-line treatment is sunitinib 50 mg daily 4/2 (I,A) or 37.5 mg continuously (III,C).”

Source: [GEIS (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10467260/)

<a id="topic-2.2.2.1.3-4"></a>

###### Third-line and fourth-line treatment

> “Regorafenib is regarded as standard therapy for the third-line treatment”
> “Ripretinib was approved by the FDA in May 2020”
> “as 4th line treatment.”

Source: [British Sarcoma Group (2024)](https://www.nature.com/articles/s41416-024-02672-0)

Additional sources: [Casali et al. (2022)](https://doi.org/10.1016/j.annonc.2021.09.005)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 TRK Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### NTRK fusion-positive disease

> “NTRK gene-fusion positive GISTs only”
> “Larotrectinib”
> “Entrectinib”

Source: [NCCN (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10245542/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 mTOR Inhibitor and Tyrosine Kinase Inhibitor Combinations

<a id="topic-2.2.2.1.5-1"></a>

###### Combination options in selected circumstances

> “TKIs to be considered for use in combination with everolimus include imatinib, sunitinib, or regorafenib.”

Source: [NCCN (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10245542/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Ablative Therapies

<a id="topic-2.2.2.1.6-1"></a>

###### Local treatment of isolated progression

> “Isolated progression may be amenable to surgery or other local measures, such as radiofrequency ablation”

Source: [British Sarcoma Group (2024)](https://www.nature.com/articles/s41416-024-02672-0)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Radiotherapy

<a id="topic-2.2.2.1.7-1"></a>

###### Local radiotherapy in advanced disease

> “Radiotherapy may be a useful local therapy”

Source: [British Sarcoma Group (2024)](https://www.nature.com/articles/s41416-024-02672-0)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Limitations of Current Therapies

<a id="topic-2.2.2.1.8-1"></a>

###### Summary

The evidence documents heterogeneous resistance mutations within and between lesions in progressing GIST. Treatment-associated symptom burden also persists: severe fatigue occurred in 30% of participants with GIST and 33% of those receiving a TKI in the cited fatigue study. These findings address resistance and treatment burden rather than demonstrating comparative efficacy between individual TKIs.

Source: [Liegl et al. (2008)](https://ohsu.elsevierpure.com/en/publications/43c092cb-e799-4ac8-8ebb-5a2479fb7bd5/); [Poort et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27233141/)

Additional sources: [Khoshnood (2019)](https://pubmed.ncbi.nlm.nih.gov/31068088/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The submitted application concerns GIST after prior imatinib treatment. The pivotal comparison evaluates bezuclastinib in combination with sunitinib rather than as monotherapy. The sponsor’s expanded-access policy requires the patient to reside in the United States and requests to be submitted by the treating physician.

Source: [Cogent Biosciences GIST new drug application submission announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-submission-new-drug-application-0); [Cogent Biosciences GIST new drug application submission initiation announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-initiate-new-drug-application-nda-submission); [Cogent Biosciences](https://cogentbio.com/bezuclastinib/)

Additional sources: [Italiano (2026)](https://pubmed.ncbi.nlm.nih.gov/42690334/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Heterogeneity of treatment resistance

> “This study demonstrates extensive intra- and inter-lesional heterogeneity of resistance mutations and gene amplification in patients with clinically progressing GIST.”

Source: [Liegl et al. (2008)](https://ohsu.elsevierpure.com/en/publications/43c092cb-e799-4ac8-8ebb-5a2479fb7bd5/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Assessment at progression during TKI therapy

> “Confirm adherence to treatment and rule out drug interactions at the time of progression to any TKI (III,B).”

Source: [GEIS (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10467260/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Progression-free survival in the pivotal comparison

> “mPFS, as assessed by blinded independent central review, was 16.5 months for the bezuclastinib combination vs. 9.2 months for sunitinib monotherapy.”

Source: [Cogent Biosciences GIST new drug application submission initiation announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-initiate-new-drug-application-nda-submission)

<a id="topic-2.2.2.7-2"></a>

###### Overall-survival maturity

> “Data for overall survival remains immature.”

Source: [Cogent Biosciences second quarter 2026 results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-11)

## Related pages
- [Bezuclastinib: Gastrointestinal stromal tumor](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Terms and abbreviations](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/terms-and-abbreviations.md)
- [Bezuclastinib: Gastrointestinal stromal tumor](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/executive-summary.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Clinical evidence](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/clinical-evidence.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Economic information and modeling report](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economics) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economics.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: References](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/references) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/references.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: prevalence by geography](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/prevalence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/prevalence.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/cost-effectiveness-analyses.md)
